High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival

[1]  M. Dubinsky,et al.  Accelerated Infliximab Dosing Increases 30-Day Colectomy in Hospitalized Ulcerative Colitis Patients: A Propensity Score Analysis. , 2018, Inflammatory bowel diseases.

[2]  K. Farkas,et al.  Prediction of Short- and Medium-term Efficacy of Biosimilar Infliximab Therapy. Do Trough Levels and Antidrug Antibody Levels or Clinical And Biochemical Markers Play the More Important Role? , 2016, Journal of Crohn's & colitis.

[3]  M. Dubinsky,et al.  Mo1908 Colectomy Free Survival is Independent of Initial Infliximab Dosing Strategy in Hospitalized Ulcerative Colitis Patients , 2016 .

[4]  C. Ponsioen,et al.  Loss of Infliximab Into Feces Is Associated With Lack of Response to Therapy in Patients With Severe Ulcerative Colitis. , 2015, Gastroenterology.

[5]  A. Vinks,et al.  Review article: applying pharmacokinetics to optimise dosing of anti‐TNF biologics in acute severe ulcerative colitis , 2015, Alimentary pharmacology & therapeutics.

[6]  P. Rutgeerts,et al.  A panel to predict long-term outcome of infliximab therapy for patients with ulcerative colitis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[7]  C. Redmond,et al.  An accelerated infliximab induction regimen reduces the need for early colectomy in patients with acute severe ulcerative colitis. , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[8]  G. Rogler,et al.  Pushing the pedal to the metal: should we accelerate infliximab therapy for patients with severe ulcerative colitis? , 2015, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[9]  J. Halfvarson,et al.  Infliximab as rescue therapy in hospitalised patients with steroid‐refractory acute ulcerative colitis: a long‐term follow‐up of 211 Swedish patients , 2013, Alimentary pharmacology & therapeutics.

[10]  M. Silverberg,et al.  Sa2031 Accelerated Clearance of Serum Infliximab During Induction Therapy for Acute Ulcerative Colitis is Associated With Treatment Failure. , 2012 .

[11]  G. Kaplan,et al.  Postoperative complications and mortality following colectomy for ulcerative colitis. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[12]  L. A. Christensen,et al.  Treatment of acute ulcerative colitis with infliximab, a retrospective study from three Danish hospitals. , 2011, Journal of Crohn's & colitis.

[13]  R. Cima.  Timing and Indications for Colectomy in Chronic Ulcerative Colitis: Surgical Consideration , 2010, Digestive Diseases.

[14]  M. Silverberg,et al.  Trough serum infliximab: a predictive factor of clinical outcome for infliximab treatment in acute ulcerative colitis , 2009, Gut.

[15]  J. Satsangi,et al.  Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. , 2005, Canadian journal of gastroenterology = Journal canadien de gastroenterologie.

[16]  Å. Danielsson,et al.  Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. , 2005, Gastroenterology.

[17]  R. Caprilli,et al.  Multiple organ dysfunction in ulcerative colitis , 2000, American Journal of Gastroenterology.

[18]  D. Jewell,et al.  Predicting outcome in severe ulcerative colitis. , 1996, Gut.

[19]  B. Rowlands,et al.  Significance of systemic endotoxaemia in inflammatory bowel disease. , 1995, Gut.

[20]  G. Järnerot,et al.  Intensive intravenous treatment of ulcerative colitis. , 1985, Gastroenterology.

[21]  C. Spicer,et al.  Assessment of severity in colitis: a preliminary study. , 1975, Gut.

[22]  D. Jewell,et al.  Intensive intravenous regimen for severe attacks of ulcerative colitis. , 1974, Lancet.

[23]  Honghui Zhou,et al.  PHARMACOKINETICS AND DISPOSITION Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis , 2009 .